CONTENTS:
- Has the treatment gap for opioid use disorder narrowed in the U.S.?: A yearly assessment from 2010 to 2019. Krawczyk N., Rivera B.D., Jent V., Keyes K.M., Jones C.M., Cerda M., art. 103786.
- Medication for opioid use disorder treatment continuity post-release from jail: A qualitative study with community-based treatment providers. Stopka T.J., Rottapel R.E., Ferguson W.J., Pivovarova E., Toro-Mejias L.D., Friedmann P.D., et al., art. 103803.
- A concept mapping study of service user design of safer supply as an alternative to the illicit drug market. Pauly B., McCall J., Cameron F., Stuart H., Hobbs H., Sullivan G., et al., art. 103849.
- Emerging pharmacological treatments for cannabis use disorder. Danilewitz M., art. 103850.
- Young people's support for various forms of e-cigarette regulation in Australia and the UK. Pettigrew S., Miller M., Santos J.A., Brown K., Morelli G., Sudhir T., et al., art. 103858.
- Maintaining HIV and HCV prevention and care for people who inject drugs despite COVID?19 in Hai Phong, Vietnam. Giang H.T., Duc N.Q., Molès J.-P., Vinh V.H., Nagot N., Thanh N.T.T., et al., art. 103870.
- Missed opportunities for healthcare providers to discuss HIV preexposure prophylaxis with people who inject drugs. Vincent W., McFarland W., art. 103873.
- Where to next? An exploration of 'night-out' location progression and propensity to experience violence in night-time entertainment precincts. Zahnow R., de Andrade D., Miller P., Taylor N., Coomber K., art. 103874.
- 'It's a different way to do medicine': Exploring the affordances of telehealth for hepatitis C healthcare. Fomiatti R., Shaw F., Fraser S., art. 103875.
- Awareness of hepatitis C virus infection status among people who inject drugs in a setting of universal direct-acting antiviral therapy: The ETHOS Engage study. Valerio H., Conway A., Alavi M., Treloar C., Silk D., Murray C., et al., art. 103876.
- Methadone and buprenorphine-related deaths among people prescribed and not prescribed Opioid Agonist Therapy during the COVID-19 pandemic in England. Aldabergenov D., Reynolds L., Scott J., Kelleher M.J., Strang J., Copeland C.S., et al., art. 103877.
- Modelling the contribution of incarceration and public health oriented drug law reform to HCV transmission and elimination among PWID in Tijuana, Mexico. Saldana C.D.R., Beletsky L., Borquez A., Kiene S.M., Marquez L.K., Strathdee S.A., et al., art. 103878.
- Opioid agonist therapy engagement and crystal methamphetamine use: The impact of unregulated opioid use in Vancouver, Canada. Cui Z., Bach P., Ti L., Hayashi K., Morgan J., Milloy M.J., et al., art. 103879.
- Consumer alcohol policies in Switzerland: A case study of Migros supermarket group. Smith A., Liebrenz M., art. 103880.
- Using synthetic controls to estimate the population-level effects of Ontario's recently implemented overdose prevention sites and consumption and treatment services. Panagiotoglou D., Lim J., art. 103881.
- U.S. state policies on opioid prescribing during the peak of the prescription opioid crisis: Associations with opioid overdose mortality. Buonora M.J., Hanna D.B., Zhang C., Bachhuber M.A., Moir L.H., Salvi P.S., et al., art. 103888.
- A stakeholder-driven framework for measuring potential change in the health risks of people who inject drugs (PWID) during the COVID-19 pandemic. Bradley H., Austin C., Allen S.T., Asher A., Bartholomew T.S., Board A., et al., art. 103889.
- Acid liberalism: Silicon Valley's enlightened technocrats, and the legalization of psychedelics. Tvorun-Dunn M., art. 103890.
- I'm just trying to stay: Experiences of temporal uncertainty in modular and supportive housing among young people who use drugs in Vancouver. Manson D., Kerr T., Fast D., art. 103893.
- Changes in supervised consumption site use and emergency interventions in Montréal, Canada in the first twelve months of the COVID-19 pandemic: An interrupted time series study. Zolopa C., Brothers T.D., Leclerc P., Mary J.-F., Morissette C., Bruneau J., et al., art. 103894.
- How Covid-19 restrictions affected young people's well-being and drinking practices: Analyzing interviews with a socio-material approach. Törrönen J., Mansson J., Samuelsson E., Roumeliotis F., Svensson J., Kraus L., et al., art. 103895.
- Review and inventory of 911 Good Samaritan Law Provisions in the United States. Reader S.W., Walton G.H., Linder S.H., art. 103896.
- Consumer experiences of long-term oral nicotine replacement therapy and related health information-seeking: A qualitative study. Grigg J., Morris E.E., Miles E., art. 103897.
- The hammer and the nail: The triple lock of methods, realities and institutional contexts in Australian research on nightlife violence. Duncan D., Moore D., Keane H., Ekendahl M., Graham K., art. 103898.
- Perceived social support moderates the association between household dysfunction adverse childhood experiences (ACEs) and self-reported drug use among men who have sex with men in Los Angeles, California. Wiss D.A., Prelip M.L., Upchurch D.M., von Ehrenstein O.S., Tomiyama A.J., Shoptaw S.J., art. 103899.
- (De)criminalisation of psychedelics in the Czech Republic - Where are we heading in drug policy and legislation? Dlestikova T., art. 103900.
- 'As for dignity and respect... me bollix': A human rights-based exploration of service user narratives in Irish methadone maintenance treatment. Healy R., Goodwin J., Kelly P., art. 103901.
- Supply-side predictors of fatal drug overdose in the Washington/Baltimore HIDTA region: 2016-2020. Lowder E.M., Zhou W., Peppard L., Bates R., Carr T., art. 103902.
- "It's professional but it's personal": Participation, personal connection, and sustained disagreement in drug policy reform. McLauchlan L., Lancaster K., Kearnes M., Mellor R., Ritter A., art. 103903.
- City streetscapes and neighborhood characteristics of fatal opioid overdoses among people experiencing homelessness who use drugs in New York City, 2017-2019. Nesoff E.D., Wiebe D.J., Martins S.S., art. 103904.